Latest Production Development News

Pacific Edge is raising NZ$24 million to shore up its finances and support a crucial Medicare re-coverage bid following a steep revenue drop after losing Medicare reimbursement for its bladder cancer test. The company eyes a draft Medicare policy by September 2026 as a potential turning point.

Unith Ltd (ASX:UNT) posted Q3 FY2026 revenue of A$1.26 million, secured a $2 million finance facility to fuel commercial expansion, and showcased significant advancements in its AI Digital Humans platform, including proprietary streaming technology and SDK launches.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

Decidr AI Industries has successfully completed a $15 million placement to fund key product development and expansion initiatives, reinforcing its lead in the agentic AI sector.

BPH Global’s Indonesian unit has locked in a four-year MoU with ITBM to integrate student-driven operations and research at its Takalar coastal seaweed site, setting the stage for scaled commercial development and local collaboration.

Acusensus Limited maintains its FY26 revenue and EBITDA guidance while advancing multiple enforcement programs across the US, UK, New Zealand, and Australia, underpinned by new product developments and international growth.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Gentrack Group trims its FY26 revenue outlook amid strategic investments and signals a $20 million on-market share buyback post-H1 results.

Arovella Therapeutics undergoes a major board overhaul and CEO resignation following a shareholder push, as the company embarks on a strategic review of its cell therapy platform.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

Ava Risk Group posted a $6.1 million Q3 sales intake and secured a $7 million strategic investment to fuel US expansion, while geopolitical tensions delay some Middle East orders.

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.